“…5 A study at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, focused on investigating the trends of resistance to the current standard anti-TB regimen and revealed the monoresistance proportion to INH was 1%, to PZN was 11.9%, and to RIF was 2%. 6 Furthermore, RIF monoresistance is rare worldwide and is usually associated with MDR TB. 7 Recent literature has shown INH monoresistance increased the likelihood of failure in treatments and relapse in patients treated with first-line anti-TB regimens.…”